Dobolyi Arpád, Ostergaard Elsebet, Bagó Attila G, Dóczi Tamás, Palkovits Miklós, Gál Aniko, Molnár Mária J, Adam-Vizi Vera, Chinopoulos Christos
Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, 1094, Hungary.
Brain Struct Funct. 2015 Jan;220(1):135-51. doi: 10.1007/s00429-013-0643-2. Epub 2013 Oct 2.
SUCLA2 encodes the ATP-forming β subunit (A-SUCL-β) of succinyl-CoA ligase, an enzyme of the citric acid cycle. Mutations in SUCLA2 lead to a mitochondrial disorder manifesting as encephalomyopathy with dystonia, deafness and lesions in the basal ganglia. Despite the distinct brain pathology associated with SUCLA2 mutations, the precise localization of SUCLA2 protein has never been investigated. Here, we show that immunoreactivity of A-SUCL-β in surgical human cortical tissue samples was present exclusively in neurons, identified by their morphology and visualized by double labeling with a fluorescent Nissl dye. A-SUCL-β immunoreactivity co-localized >99 % with that of the d subunit of the mitochondrial F0-F1 ATP synthase. Specificity of the anti-A-SUCL-β antiserum was verified by the absence of labeling in fibroblasts from a patient with a complete deletion of SUCLA2. A-SUCL-β immunoreactivity was absent in glial cells, identified by antibodies directed against the glial markers GFAP and S100. Furthermore, in situ hybridization histochemistry demonstrated that SUCLA2 mRNA was present in Nissl-labeled neurons but not glial cells labeled with S100. Immunoreactivity of the GTP-forming β subunit (G-SUCL-β) encoded by SUCLG2, or in situ hybridization histochemistry for SUCLG2 mRNA could not be demonstrated in either neurons or astrocytes. Western blotting of post mortem brain samples revealed minor G-SUCL-β immunoreactivity that was, however, not upregulated in samples obtained from diabetic versus non-diabetic patients, as has been described for murine brain. Our work establishes that SUCLA2 is expressed exclusively in neurons in the human cerebral cortex.
SUCLA2编码琥珀酰辅酶A连接酶的ATP合成β亚基(A-SUCL-β),该酶是柠檬酸循环中的一种酶。SUCLA2突变会导致一种线粒体疾病,表现为伴有肌张力障碍、耳聋和基底神经节病变的脑肌病。尽管SUCLA2突变与独特的脑部病理相关,但SUCLA2蛋白的精确定位从未被研究过。在这里,我们表明,在手术获取的人类皮质组织样本中,A-SUCL-β的免疫反应性仅存在于神经元中,通过其形态学鉴定,并通过与荧光尼氏染料双重标记进行可视化。A-SUCL-β免疫反应性与线粒体F0-F1 ATP合酶d亚基的免疫反应性共定位>99%。通过对SUCLA2完全缺失患者的成纤维细胞无标记来验证抗A-SUCL-β抗血清的特异性。通过针对胶质细胞标志物GFAP和S100的抗体鉴定,胶质细胞中不存在A-SUCL-β免疫反应性。此外,原位杂交组织化学表明,SUCLA2 mRNA存在于尼氏染色的神经元中,但不存在于用S100标记的胶质细胞中。在神经元或星形胶质细胞中均未检测到SUCLG2编码的GTP形成β亚基(G-SUCL-β)的免疫反应性,也未检测到SUCLG2 mRNA的原位杂交组织化学信号。对死后脑样本的蛋白质免疫印迹分析显示,G-SUCL-β免疫反应性较弱,然而,与小鼠脑的情况不同,在糖尿病患者与非糖尿病患者的样本中,其并未上调。我们的研究确定,SUCLA2仅在人类大脑皮质的神经元中表达。